Evidence map›Paper›PMID 23973710›Full record

ArticleBiochemical and biophysical research communications2013

miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells.

Hung Pham, C Ekaterina Rodriguez, Graham W Donald, Kathleen M Hertzer, Xiaoman S Jung, Hui-Hua Chang, Aune Moro, Howard A Reber, O Joe Hines, Guido Eibl

Open access · greenAbstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 60 citations in OpenAlex.

  1. Fever Inspiration: Precision Engineering for Safe and Systemic Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Noncoding RNAs: the shot callers in tumor immune escape.Signal transduction and targeted therapy · 2020
    Review
  12. Article
  13. Article
  14. Transcription Factor RREB1: from Target Genes towards Biological Functions.International journal of biological sciences · 2020
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hung PhamDepartment of Surgery, UCLA Center of Excellence in Pancreatic Diseases, UCLA David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, United States; Department of Medicine, Veterans Affair Greater Los Angeles Healthcare System, Los Angeles, CA 90073, United States.
C Ekaterina Rodriguez
Graham W Donald
Kathleen M Hertzer
Xiaoman S Jung
Hui-Hua Chang
Aune Moro
Howard A Reber
O Joe Hines
Guido Eibl
University of California, Los Angeles · US

Funding

Targeting diet-induced promotion of Kras-initiated pancreatic adenocarcinomaP01CA163200 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EIBL, GUIDO ERWIN MICHAEL · 2012 to 2016
$6.2M
NCI NIH HHS P01 CA163200NCI NIH HHS P01CA163200
6 · The paper itself

Abstract

Small non-coding RNAs, microRNAs (miRNA), inhibit the translation or accelerate the degradation of message RNA (mRNA) by targeting the 3'-untranslated region (3'-UTR) in regulating growth and survival through gene suppression. Deregulated miRNA expression contributes to disease progression in several cancers types, including pancreatic cancers (PaCa). PaCa tissues and cells exhibit decreased miRNA, elevated cyclooxygenase (COX)-2 and increased prostaglandin E2 (PGE2) resulting in increased cancer growth and metastases. Human PaCa cell lines were used to demonstrate that restoration of miRNA-143 (miR-143) regulates COX-2 and inhibits cell proliferation. miR-143 were detected at fold levels of 0.41 ± 0.06 in AsPC-1, 0.20 ± 0.05 in Capan-2 and 0.10 ± 0.02 in MIA PaCa-2. miR-143 was not detected in BxPC-3, HPAF-II and Panc-1 which correlated with elevated mitogen-activated kinase (MAPK) and MAPK kinase (MEK) activation. Treatment with 10 μM of MEK inhibitor U0126 or PD98059 increased miR-143, respectively, by 187 ± 18 and 152 ± 26-fold in BxPC-3 and 182 ± 7 and 136 ± 9-fold in HPAF-II. miR-143 transfection diminished COX-2 mRNA stability at 60 min by 2.6 ± 0.3-fold in BxPC-3 and 2.5 ± 0.2-fold in HPAF-II. COX-2 expression and cellular proliferation in BxPC-3 and HPAF-II inversely correlated with increasing miR-143. PGE2 levels decreased by 39.3 ± 5.0% in BxPC-3 and 48.0 ± 3.0% in HPAF-II transfected with miR-143. Restoration of miR-143 in PaCa cells suppressed of COX-2, PGE2, cellular proliferation and MEK/MAPK activation, implicating this pathway in regulating miR-143 expression.

Indexed as

Gene Expression Regulation, NeoplasticRNA StabilityButadienesCell Line, TumorCell ProliferationCyclooxygenase 2DinoprostoneDNA-Binding ProteinsEnzyme InhibitorsFlavonoidsHumansMAP Kinase Kinase KinasesMicroRNAsNitrilesp38 Mitogen-Activated Protein KinasesPancreatic Neoplasms2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneButadienesCyclooxygenase 2DinoprostoneDNA-Binding ProteinsEnzyme InhibitorsFlavonoidsMAP Kinase Kinase KinasesMicroRNAsMIRN143 microRNA, humanNitrilesp38 Mitogen-Activated Protein KinasesPTGS2 protein, humanRNA, MessengerRREB1 protein, humanTranscription FactorsU 01263-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromideCOX-2CREBcyclic AMP responsive element binding proteincyclooxygenase-2Cyclooxygenase-2MAPKMAPK kinaseMEKmicroRNA-143miR-143mitogen-activated protein kinaseMTTPaCapancreatic cancerPancreatic cancerPGE(2)PKAprostaglandin E(2)Prostaglandin E(2)protein kinase Aras responsive element binding proteinRREB1

Identifiers

PMID23973710
PMCPMC3789599
OpenAlexW2150369367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.